How to Get Tirzepatide: Your Options in 2026
Tirzepatide is FDA approved. Here are your current access pathways — telehealth, clinic, and compounding options.
FDA approved. Requires prescription. Available via physician or telehealth provider.
Option 1: Telehealth Platforms
Telehealth platforms have made GLP-1 and GLP-3 agonists far more accessible. You can get an online consultation and, if eligible, a prescription filled at a licensed pharmacy or compounding pharmacy.
Frequently Asked Questions
How can I get Tirzepatide right now?
Tirzepatide is FDA approved and can be prescribed by a licensed physician. Telehealth platforms and weight management clinics are the most accessible options.
Is Tirzepatide available without a prescription?
No. Tirzepatide requires a valid prescription from a licensed healthcare provider.
Can I join a Tirzepatide clinical trial?
Yes. Eli Lilly is running Phase 3 TRIUMPH trials for Retatrutide. You can search active trials at ClinicalTrials.gov using the identifier NCT05703841 or by searching "retatrutide." Trials typically require BMI ≥ 30 (or ≥ 27 with a weight-related condition) and no recent GLP-1 use.
When will Tirzepatide be available to the general public?
Based on current Phase 3 timelines and Eli Lilly's projected FDA filing in 2026–2027, Tirzepatide could be available via prescription by 2027–2028 if approved on schedule.
Exploring Retatrutide Access?
See how patients are accessing retatrutide through physician-supervised telehealth and compounding pharmacies.
Not FDA approved. Access requires physician oversight.
Affiliate links — we may earn a commission at no cost to you.